Galibert and Deramond first introduced the technique of percutaneous vertebroplasty with polymethylmethacrylate (PMMA) as a reinforcement procedure for the treatment of vertebral angiomas in 1987 [26]. Following encouraging early clinical results, particularly with respect to pain relief, indications for PMMA augmentation were extended. At present, osteoporotic compression fractures of the spine represent the most important indication for vertebroplasty, followed by metastatic bone diseases. Clinical series of vertebroplasty almost exclusively report the use of PMMA; however, several disadvantages have been recognized and described [16, 18, 25, 31, 32, 36, 53] . PMMA cures with a strongly exothermic reaction, potentially damaging adjacent soft tissue structures, particularly in the event of cement extrusion. In addition, with maximal PMMA filling, adjacent vertebral overload has been reported, possibly provoking fractures [6] (Fig. 1a,b) . For the purpose of vertebral augmentation, PMMA seems to be a successful, but not an optimal material. Researchers and clinicians therefore have to consider and evaluate alternative substances for use in vertebroplasty.
Introduction
Galibert and Deramond first introduced the technique of percutaneous vertebroplasty with polymethylmethacrylate (PMMA) as a reinforcement procedure for the treatment of vertebral angiomas in 1987 [26] . Following encouraging early clinical results, particularly with respect to pain relief, indications for PMMA augmentation were extended. At present, osteoporotic compression fractures of the spine represent the most important indication for vertebroplasty, followed by metastatic bone diseases. Clinical series of vertebroplasty almost exclusively report the use of PMMA; however, several disadvantages have been recognized and described [16, 18, 25, 31, 32, 36, 53] . PMMA cures with a strongly exothermic reaction, potentially damaging adjacent soft tissue structures, particularly in the event of cement extrusion. In addition, with maximal PMMA filling, adjacent vertebral overload has been reported, possibly provoking fractures [6] (Fig. 1a,b) . For the purpose of vertebral augmentation, PMMA seems to be a successful, but not an optimal material. Researchers and clinicians therefore have to consider and evaluate alternative substances for use in vertebroplasty.
Bone substitutes have always been an important issue in orthopedics, especially in spine surgery. The use of (solid) autogenous bone grafts (iliac crest, ribs, fibulae) is associated with considerable morbidity and mechanical limitations [3, 14, 23] (Fig. 2a-c) . PMMA was and still is the material of choice for defect reconstruction, especially in palliative treatment of spinal metastasis [33] . Allografts have a long history as a bone substitute, but their value remains controversial [11, 13, 56] . Bone growth factors show an enormous potential with encouraging experimental and initial clinical results [8, 9, 10, 49] .
Abstract Vertebroplasty -percutaneous cement augmentation of vertebral bodies -is an efficient procedure for the treatment of painful vertebral fractures in osteoporosis. At the present time, polymethylmethacrylate (PMMA) is the only available cement with reports of clinical application and experience. The material is easy to handle, the radiopacity can be adapted by adding contrast dye, and it is mechanically efficient. Composite cements (acrylic cements in conjunction with ceramics) are bioactive, highly radiopaque, and feature excellent mechanical properties. One such cement, Cortoss, is currently undergoing clinical trials for vertebroplasty and has so far been shown to be a potentially valuable alternative to PMMA. Several in vitro studies with injectable calcium phosphate (CaP) cements show their feasibility and mechanical effectiveness. Animal studies confirm their biocompatibility and osteoconductivity. However, handling problems and the limited radiopacity of these cements currently preclude their clinical use.
Contemporary bone substitutes
Several bone substitutes are in clinical use, mainly as bone graft expanders for spinal fusion [8, 22, 28, 29, 34, 43, 45, 46, 57] . Biomaterials (materials intended to interface with biological systems to evaluate, treat, augment, or replace any tissue, organ, or function of the body [54] For the clinician, it is extremely difficult to approach this topic and survey the numerous products on the market. We have therefore tried to list the most common bone substitutes available in Europe and United States and focused on injectable bone cements (Tables 1, 2 ). The information on the products were obtained from the literature and from the Internet. However, we cannot guarantee that it is comprehensive. The same cement material is sometimes marketed by different distributors under different brand names (i.e., α-BSM is produced by Etex and sold in Europe by Merck as Biobon and in the United States by Lorenz Surgical as embarc). Furthermore, basic knowledge about bone cements is required in order to understand important details of different substances. Several articles concerning this issue help to close an existing gap in this field.
Bone substitutes for vertebroplasty
Requirements for an ideal augmentation material A bone substitute for vertebroplasty needs to have the following properties:
• Injectability • Ease of handling • High radiopacity • Adapted viscosity (not too low)
• Lasting, constant viscosity (5-10 min)
• Long setting time (≈15 min)
• Low curing temperature • Adapted, lasting mechanical properties
An optimal bone substitute for vertebroplasty must be easy to apply, i.e., the components are easy to handle, the mixing procedure is simple, and the material can be applied percutaneously through cannulas into the vertebral body. This requires a low initial viscosity of the material, which has to be balanced against potential extravasation if the material is too liquid. Sufficient radiopacity is of utmost importance in order to be able to follow the cement flow. The setting time should be about 10 min, and viscosity of the cement should remain constant during this period to allow controlled application. The curing temperature must be as low as possible. The optimal mechanical properties (i.e., compressive strength/stiffness) have not yet been defined. Following the operative procedure, the material should provide immediate reinforcement of the vertebral body and allow early ambulation of the patients. Stiffness and yield strength should resemble values of natural bone. Excessively high stress differences in comparison to nonaugmented areas should be avoided. Finally, reinforcement should not deteriorate over time.
The material must not cause adverse reactions in the surrounding tissue. A bioactive cement seems to be advantageous; however, whether or not a biodegradable cement is important is an open question.
Finally, the material should be reasonably priced in order to allow wide-spread application from the point of view of cost-effectiveness and economic restrains.
At present, different compositions of injectable bone substitutes are available ( . This material seems to be advantageous compared with PMMA as it features an optimal and constant viscosity (the components are mixed in the extrusion cannula) and a high radiopacity. Furthermore, the curing temperature is lower than that of regular PMMA. These properties, together with a good penetration into the cancellous bone, reduce the risk if extravasation. Clinical trials on vertebroplasty with this cement are currently being performed. The remaining materials presented in this article are not ready for clinical use for vertebroplasty at this time. Most of these cements were designed for dentistry and S210 craniofacial surgery and have proven to be biologically suitable. The need for appropriate bone substitutes in spine surgery, especially in vertebroplasty, has lead to these products being evaluated and adapted for these new applications. All the information on injectable bone cements has been summarized here, with a special focus on materials that have been tested in vitro for vertebroplasty or screw fixation in the spine. Kuraray is producing a composite cement of hydroxyapatite (HA) and an acrylic monomer (CAP) that seems to be easy to handle. It shows some bioactivity and a high mechanical performance [48] . In vitro tests on pedicle screw fixation have been performed, but not on vertebroplasty [52] .
Calcium phosphate cements
Bone Source is an injectable cement primarily designed to repair cranial defects. Lim et al. tested PMMA and Bone Source in vertebral bodies in an axial compression model and achieved a significant increase of yield strength for intact reinforced vertebrae in comparison to the native state. This was more pronounced for PMMA, whereas the increase of a fractured vertebrae was only significant with PMMA but not with calcium phosphate (CaP) [44] . Belkoff compared the use of Bone Source and PMMA in isolated vertebral bodies in an axial compression model and again found a significant increase of the peak load for PMMA; however, CaP cement did not improve the mechanical properties [5] .
Schildhauer published a report on the use of Norian for reinforcement of vertebral bodies. Filling could only be achieved by using an irrigation/suction/injection technique. The amount of cement injected is not reported. An increase in energy absorption was able to be achieved, but only the vertebral body height had been reduced by 50%. The change in yield strength and stiffness is not reported [51] . Heini used Norian for in vitro reinforcement of vertebral bodies; however, its material properties precluded application through a cannula, as it separated under pressure to the liquid and solid phase [30] . However, its usefulness as a bone substitute in other applications was able to be demonstrated [15] .
Biopex is a bone cement with remarkable mechanical properties. Experimental data are available on its use for screw fixation in femoral neck fractures [50] . No further tests have been performed. Personal in vitro handling tests show that the cement can be injected very easily over a long period. Its biological behavior was assessed in a rabbit mandibula model [41] .
Biobon (or α-BSM or embarc) is a CaP cement that was originally designed for dentistry and craniofacial surgery. Its mechanical efficacy in a vertebroplasty model was assessed and compared with PMMA and shows a significant effect [2, 39] . Whether its radiopacity and handling will allow clinical application is not clear.
Mimix is a cement designed and approved for craniofacial surgery. No test results or information is available for vertebroplasty.
Cementek is a cement paste with suitable mechanical properties. No experience in clinical use has been reported for any application. Its biological behavior was assessed in a rabbit mandibula defect model [27, 42] .
EBS (end product: experimental brushite cement) shows good mechanical properties and biological behavior. A biomechanical study on a vertebroplasty model showed a significant increase in the yield strength and stifness [31, 35] . There are no clinical data available yet.
Collagraft is a paste consisting of CaP cement and bovine collagen. This bone substitute has already been in clinical use for a long time and has proved to be useful for long bone defects and spinal fusion [10, 12, 57] . No information on its mechanical properties or experimental data on vertebroplasty is available.
Biocement D is a calcium-deficient HA cement containing dicalcium phosphate (DCP) and collagen in order to improve the injectability [37, 38] . No further information is available regarding mechanical or biological properties.
Drake et al. compared the stability of a thoracic spine specimen (T7-L1) in a T11 fracture model intact or reinforced with PMMA or HA cement (Howmedica). The three-dimensional load displacement behavior showed significant restoration of stability for both materials following destabilization. There are no further specifications regarding the cement [21] .
Conclusion
An optimized cement formula is definitely required for vertebroplasty. The disadvantages of PMMA are its high curing temperature and the potential adverse biological effects. Vertebroplasty has become an important treatment option and has a great potential. There are some promising cements under development, and several of these products will likely soon be available.
Optimal viscosity and sufficient radiopacity are the most important parameters to be addressed. The optimal mechanical properties and filling patterns required for optimal reinforcement need to be evaluated further. It seems that PMMA augmentation leads to a significant increase in vertebral body stiffness, thereby increasing the risk of fractures at adjacent vertebral bodies [6] . On the other hand, it does not seem reasonable to reinforce vertebrae in such manner that their mechanical properties only improve after a considerable collapse has already occurred [51] . Biodegradation is an open question: When treating osteoporotic vertebral fractures by cement augmentation, fast cement resorption without new bone formation will have a contrary effect, as the induced resorption may weaken the vertebral body and promote further collapse. It would be useful to assess the biological behavior and dynamics of biodegradation in a standardized animal model (i.e., osteoporotic sheep).
The material most appropriate for our patients will eventually be a bioactive/slowly resorbable cement with mechanical properties comparable to a healthy vertebral body (not equal to cancellous bone) with an adapted viscosity and high radiopacity, available at a reasonable price. 
